Fundraise

France's Resilience raises €48M to expand beyond cancer care

What's the deal? Paris-based digital health company ResilienceDealroom has a profile for this one. Try Dealroom → has raised €48 million ($53.5 million) in a growth equity round led by US firm PSGDealroom has a profile for this one. Try Dealroom → Equity. The company runs a remote monitoring platform, built with France's Gustave Roussy cancer institute, that lets medical teams track patients with chronic diseases.

What's the endgame? Resilience plans to move beyond its oncology base into psychiatry and gastroenterology, using acquisitions to scale. The financing brings total funding since 2021 to more than €105 million. The company aims to reach group-level profitability by the second quarter of 2027.

The expansion: Growth will reach across both conditions and borders. Resilience has partnerships with 12 healthcare facilities in Germany, acquired German psychiatric monitoring startup Recovery Cat in September 2026, and recruited a US commercial team. PSG Equity's capital will fund further deals, including firms with established reimbursement arrangements.

Why it matters? The platform has supported more than 40,000 oncology patients across roughly 200 French healthcare institutions, founded by Céline Lazorthes and Jonathan Benhamou. The round ranks around the 91st percentile for growth equity healthtech deals in France over the trailing 48 months, among 78 comparable rounds.

The signal: Resilience's round lands amid a mixed French healthtech picture. France Biotech reported €1 billion in healthtech venture funding in 2025, up 15% year on year, but said only one in five companies raised money. The deal reads less as a broad funding boom than as a sizeable bet on one care model's ability to expand across conditions and markets.

Read more: frenchtechjournal.com

Image credit: Generated with Gemini

More top stories